DBV TECHNOLOGIES (EPA:DBV) | WebDisclosure

Basculer en Français

10371	Companies
216158	Keywords
145874	Articles
114457	Press releases

Home
Companies
DBV TECHNOLOGIES

PRESS RELEASE

published on 11/12/2025 at 05:50, 5 months 26 days ago

DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides
DBV Technologies annonce la fin de la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants allergiques aux arachides, se rapprochant ainsi de la publication des résultats préliminaires

Essai Clinique DBV Technologies Patch Viaskin Peanut Enfants Allergiques Phase 3 VITESSE
BRIEF

published on 11/04/2025 at 22:35, 6 months 4 days ago

DBV Technologies is participating in a healthcare innovation conference

DBV Technologies Viaskin Food Allergies Health Conference EPIT
BRIEF

published on 11/04/2025 at 22:35, 6 months 4 days ago

DBV Technologies participe à une conférence sur l'innovation en santé

DBV Technologies Allergies Alimentaires Viaskin Conférence Santé EPIT
PRESS RELEASE

published on 11/04/2025 at 22:30, 6 months 4 days ago

DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
DBV Technologies to participate in Guggenheim 2nd Annual Healthcare Innovation Conference with CEO Daniel Tassé at the helm, discussing treatment options for food allergies

Healthcare Innovation DBV Technologies Food Allergies VIASKIN Patch Guggenheim Conference
PRESS RELEASE

published on 11/04/2025 at 22:30, 6 months 4 days ago

DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation
DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation avec Daniel Tassé, Directeur Général. Découvrez la webdiffusion en direct sur le patch VIASKIN® pour les allergies alimentaires

Conférence Annuelle DBV Technologies Allergies Alimentaires Patch VIASKIN® Guggenheim Healthcare Innovation
BRIEF

published on 10/30/2025 at 21:35, 6 months 9 days ago

DBV Technologies Appoints Philina Lee, Ph.D. to Board of Directors

Board Of Directors Biopharmaceutical DBV Technologies Viaskin Peanut Philina Lee
BRIEF

published on 10/30/2025 at 21:35, 6 months 9 days ago

DBV Technologies nomme Philina Lee, Ph.D., à son conseil d'administration

Conseil D'administration Biopharmaceutique VIASKIN Cacahuète Philina Lee Technologies DBV
PRESS RELEASE

published on 10/30/2025 at 21:30, 6 months 9 days ago

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
DBV Technologies appoints Dr. Philina Lee, Ph.D. as independent director to Board of Directors, bringing extensive biopharmaceutical experience. Company focused on VIASKIN® Peanut for food allergies

Board Of Directors DBV Technologies Food Allergies Viaskin Peanut Dr. Philina Lee
PRESS RELEASE

published on 10/30/2025 at 21:30, 6 months 9 days ago

DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration
DBV Technologies nomme Philina Lee, Ph.D. au Conseil d’administration et Comité des rémunérations. Lee apporte son expertise en biopharmaceutique et commercialisation. DBV se concentre sur le traitement des allergies alimentaires

Conseil D'administration Biopharmaceutique DBV Technologies Allergies Alimentaires Philina Lee
BRIEF

published on 10/28/2025 at 21:30, 6 months 11 days ago

DBV Technologies annonce ses résultats financiers du T3 2025

Résultats Financiers Financement Trésorerie Perte Nette Viaskin Peanut

Accesswire

Published on 05/09/2026 at 00:00, 1 hour 27 minutes ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 2 hours 26 minutes ago

Water Ways Announces Corporate Updates
Published on 05/08/2026 at 23:00, 2 hours 27 minutes ago

Digi Power X Announces Upsizing of At-the-Market Offering Program
Published on 05/08/2026 at 22:30, 2 hours 57 minutes ago

Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
Published on 05/08/2026 at 22:30, 2 hours 57 minutes ago

Sekur Private Data Advances Defense-Grade Secure Communications Platform

View all ACCESSWIRE

EQS Group

Published on 05/08/2026 at 20:38, 4 hours 49 minutes ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 6 hours 14 minutes ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 6 hours 24 minutes ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 6 hours 58 minutes ago

Designated Person Notification
Published on 05/08/2026 at 18:29, 6 hours 58 minutes ago

Designated Person Notification

Les Echos

Published on 05/07/2026 at 19:15, 1 day 6 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 6 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 6 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 6 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 6 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE